



## **EGF THERAMED HEALTH CORP. RAISES \$270,000 IN SECOND TRANCHE OF PRIVATE PLACEMENT**

**Vancouver, B.C., April 29, 2020** – EGF THERAMED HEALTH CORP. (CSE: TMED, OTCQB: EVAHF) (the “**Company**”) is pleased to announce that it has completed the second tranche of its previously announced (dated April 13, 2020) non-brokered private placement.

The Company has closed on an additional 540,000 units at a price of \$0.50 per unit for gross proceeds of \$270,000. Each unit consists of one common share and one common share purchase warrant, with each warrant entitling the holder to acquire one additional common share of the Company at a price of \$0.75 for a period of 18 months from the closing of the offering. All securities issued in the second tranche offering are subject to a hold period expiring on August 29, 2020.

The net proceeds from the non-brokered private placement are intended to be used for working capital and acquisitions.

The Company has increased its efforts in researching psilocybin and psychedelic extraction and processing for its Las Vegas extraction lab. Specifically, the Company is researching psilocybin micro-dosing and its effects on reducing stress, anxiety and pain without the side effects associated with traditional pharmacology products.

David Bentil, CEO of the Company, stated, “We are evaluating multiple projects that we feel have considerable upside potential that go hand in hand with our existing assets. We believe that CBD and psilocybin carry unique and undeniable health benefits.”

In addition, the Company announces that it intends to grant 175,000 stock options to certain directors of the Company, with each option exercisable at \$1.10 for twenty-four months from the date of issuance.

For more information please contact:

### **EGF THERAMED HEALTH CORP.**

Contact: David Bentil, CEO

Email [theramedhealthcorp@gmail.com](mailto:theramedhealthcorp@gmail.com)

Telephone: (778) 559-3939

Website <http://www.theramedhealthcorp.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/Theramed-Health-Corporation>

US OTC Markets (OTCQB): <http://www.otcmarkets.com/stock/EVAHF/news>

## **About EGF Theramed Health Corp.**

EGF Theramed Health Corp. is a consumer technology company engaged in the provision of biomedical online services for monitoring and treating common health problems. The Company, through its subsidiaries, has assets and technologies used in the extraction and purification of botanical extracts and the creation of extract formulations, as well as medical monitoring device technology. The Company is seeking to be the first company to offer a complete quality assured vertically integrated “Natural Products and Herbal Health System” for monitoring, dosing, and recording the effects of natural products on the cardiovascular system.

### **DISCLAIMERS**

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the use of funds raised in the private placement, option grant, its research into psilocybin and its mission to become the first company to offer a “Natural Products and Herbal Health System” for monitoring, dosing, and recording the effects of natural products on the cardiovascular system. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company’s public filings under the Company’s SEDAR profile at [www.sedar.com](http://www.sedar.com). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.